Condition: Multiple Myeloma · Multiple Myeloma in Relapse · Multiple Myeloma, Refractory · Sponsor: Bioray Laboratories
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
This description comes directly from the study's public registry record.
Ping Li, phD · 13564181131 · lilyforever76@126.com
Always discuss trial participation with your own doctor first.
| Shanghi Tongji Hospital (Tongji Hospital of Tongji University) | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07248176